These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11689849)

  • 1. A yeast sensor of ligand binding.
    Tucker CL; Fields S
    Nat Biotechnol; 2001 Nov; 19(11):1042-6. PubMed ID: 11689849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making drug addicts out of yeast.
    Vidan S; Snyder M
    Nat Biotechnol; 2001 Nov; 19(11):1022-3. PubMed ID: 11689844
    [No Abstract]   [Full Text] [Related]  

  • 3. A genetic, non-transcriptional assay for nuclear receptor ligand binding in yeast.
    Köhler F; Zimmermann A; Hager M; Sippel AE
    Gene; 2004 Aug; 337():113-9. PubMed ID: 15276207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colocalization and ligand-dependent discrete distribution of the estrogen receptor (ER)alpha and ERbeta.
    Matsuda K; Ochiai I; Nishi M; Kawata M
    Mol Endocrinol; 2002 Oct; 16(10):2215-30. PubMed ID: 12351687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast three-hybrid system for detecting ligand-receptor interactions.
    Griffith EC; Licitra EJ; Liu JO
    Methods Enzymol; 2000; 328():89-103. PubMed ID: 11075340
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlation between ligand-receptor affinity and the transcription readout in a yeast three-hybrid system.
    de Felipe KS; Carter BT; Althoff EA; Cornish VW
    Biochemistry; 2004 Aug; 43(32):10353-63. PubMed ID: 15301533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescent cellular sensors of steroid receptor ligands.
    Muddana SS; Peterson BR
    Chembiochem; 2003 Sep; 4(9):848-55. PubMed ID: 12964159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells.
    Wooge CH; Nilsson GM; Heierson A; McDonnell DP; Katzenellenbogen BS
    Mol Endocrinol; 1992 Jun; 6(6):861-9. PubMed ID: 1495491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An FKBP12 binding assay based upon biotinylated FKBP12.
    Carreras CW; Fu H; Santi DV
    Anal Biochem; 2001 Nov; 298(1):57-61. PubMed ID: 11673895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a yeast protein fragment complementation assay (PCA) system using dihydrofolate reductase (DHFR) with specific additives.
    Shibasaki S; Sakata K; Ishii J; Kondo A; Ueda M
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):735-43. PubMed ID: 18670770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-dependent protein interactions of the estrogen receptors using the yeast two-hybrid system.
    Oftedal BE; Ladstein S; Telle W; Male R
    Ann N Y Acad Sci; 2005 Apr; 1040():420-5. PubMed ID: 15891078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly efficient and sensitive screening method for trans-activation activity of estrogen receptors.
    Chen Z; Zhao H
    Gene; 2003 Mar; 306():127-34. PubMed ID: 12657474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of the human prolyl isomerase FKBP12 with unrelated chaperone domains leads to chimeric folding enzymes with high activity.
    Geitner AJ; Schmid FX
    J Mol Biol; 2012 Jul; 420(4-5):335-49. PubMed ID: 22542528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile.
    Sun J; Baudry J; Katzenellenbogen JA; Katzenellenbogen BS
    Mol Endocrinol; 2003 Feb; 17(2):247-58. PubMed ID: 12554752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Function of N-terminal transactivation domain of the estrogen receptor requires a potential alpha-helical structure and is negatively regulated by the A domain.
    Métivier R; Petit FG; Valotaire Y; Pakdel F
    Mol Endocrinol; 2000 Nov; 14(11):1849-71. PubMed ID: 11075817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Nichols M; Rientjes JM; Logie C; Stewart AF
    Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor.
    Koide A; Abbatiello S; Rothgery L; Koide S
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1253-8. PubMed ID: 11818562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the yeast one-hybrid system to screen for mutations in the ligand-binding domain of the estrogen receptor.
    Bush SM; Folta S; Lannigan DA
    Steroids; 1996 Mar; 61(3):102-9. PubMed ID: 8852826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.
    Schaufele F; Chang CY; Liu W; Baxter JD; Nordeen SK; Wan Y; Day RN; McDonnell DP
    Mol Endocrinol; 2000 Dec; 14(12):2024-39. PubMed ID: 11117532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FKBP and DHFR based destabilizing domains in Saccharomyces cerevisiae.
    Rakhit R; Edwards SR; Iwamoto M; Wandless TJ
    Bioorg Med Chem Lett; 2011 Sep; 21(17):4965-8. PubMed ID: 21741238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.